Portulaca oleracea Seed Oil Exerts Cytotoxic Effects on Human Liver Cancer (HepG2) and Human Lung Cancer (A-549) Cell Lines

  • Published : 2015.04.29


Portulaca oleracea (Family: Portulacaceae), is well known for its anti-inflammatory, antioxidative, anti-bacterial, and anti-tumor activities. However, cytotoxic effects of seed oil of Portulaca oleracea against human liver cancer (HepG2) and human lung cancer (A-549) cell lines have not been studied previously. Therefore, the present study was designed to investigate the cytotoxic effects of Portulaca oleracea seed oil on HepG2 and A-549 cell lines. Both cell lines were exposed to various concentrations of Portulaca oleracea seed oil for 24h. After the exposure, percentage cell viability was studied by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT), neutral red uptake (NRU) assays, and cellular morphology by phase contrast inverted microscopy. The results showed a concentration-dependent significant reduction in the percentage cell viability and an alteration in the cellular morphology of HepG2 and A-549 cells. The percentage cell viability was recorded as 73%, 63%, and 54% by MTT assay and 76%, 61%, and 50% by NRU assay at 250, 500, and $1000{\mu}g/ml$, respectively in HepG2 cells. Percentage cell viability was recorded as 82%, 72%, and 64% by MTT assay and 83%, 68%, and 56% by NRU assay at 250, 500, and $1000{\mu}g/ml$, respectively in A-549 cells. The 100 $100{\mu}g/ml$ and lower concentrations were found to be non cytotoxic to A-549 cells, whereas decrease of 14% and 12% were recorded by MTT and NRU assay, respectively in HepG2 cells. Both HepG2 and A-549 cell lines exposed to 250, 500, and $1000{\mu}g/ml$ of Portulaca oleracea seed oil lost their normal morphology, cell adhesion capacity, become rounded, and appeared smaller in size. The data from this study showed that exposure to seed oil of Portulaca oleracea resulted in significant cytotoxicity and inhibition of growth of the human liver cancer (HepG2) and human lung cancer (A-549) cell lines.


Supported by : NSTIP


  1. Alam MA, Juraimi AS, Rafii MY, et al (2014). Evaluation of antioxidant compounds, antioxidant activities, and mineral composition of 13 collected purslane (Portulaca oleracea L.) accessions. BioMed Res Intern, 96063, 1-10.
  2. Al-Oqail MM, Farshori NN, Al-Sheddi ES, et al (2013). In vitro cytotoxic activity of seed oil of fenugreek against various cancer cell lines. Asian Pac J Cancer Prev, 14, 1829-32.
  3. Al-Sheddi ES, Farshori NN, Al-Oqail MM, et al (2014). Cytotoxicity of Nigella sativa seed oil and extract against human lung cancer cell line. Asian Pacific J Cancer Prev, 15, 983-7.
  4. Bidhendi F, Ahmadi R, Siavashi M, et al (2014). The effects of Portulaca oleracea seed extract on RBC membrane stability in male and female rats. international conference on food, biological and medical sciences (FBMS-2014), January 28-29, Bangkok (Thailand).
  5. Chan K, Islam MW, Kamil M, et al (2000). The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. Sativa (Haw.) Celak. J Ethnopharmacol, 73, 445-51.
  6. Chen T, Wang J, Li Y, et al (2010). Sulfated modification and cytotoxicity of Portulaca oleracea L. polysaccharides. Glycoconj J, 27, 635-42.
  7. Chen T-J, Jeng J-Y, Lin C-W, et al (2006). Quercetin inhibition of ROS-dependent and independent apoptosis in rat glioma C6 cells. Toxicology, 1-2, 113-26.
  8. Dkhil MA, Abdel Moniem A, Al-Quraishy S, et al (2011). Antioxidant effect of purslane (Portulaca oleracea) and its mechanism of action. J Med Plant Research, 5, 1589-93.
  9. Ezekwe MO, Omara-Alwala TR, Membrahtu T (1999). Nutritive characterization of purslane accessions as influenced by planting date. Plant Foods Hum Nutr, 54, 183-91.
  10. Farshori NN, Al-Sheddi ES, Al-Oqail MM, et al (2013). Anticancer activity of Petroselinum sativum seed extracts on MCF-7 human breast cancer cells. Asian Pac J Cancer Prev, 14, 5719-23.
  11. Farshori NN, Al-Sheddi ES, Al-Oqail MM, et al (2014). Cytotoxicity assessments of Portulaca oleracea and Petroselinum sativum seed extracts on human hepatocellular carcinoma cells (HepG2). Asian Pac J Cancer Prev, 15 (16), 6633-8.
  12. Fazeli Z, Pourhoseingholi MA, Vahedi M, Zali MR (2012). Burden of hepatocellular carcinoma in Asia. Asian Pac J Cancer Prev, 13, 5955-58.
  13. Frei E (1982). The national cancer chemotherapy program. Science, 217, 600-6.
  14. Handique JG, Boruah MP, Kalita D (2012). Antioxidant activities and total phenolic and flavonoid contents in three indigenous medicinal vegetables of north-east India. Nat Prod Commun, 7, 1021-3.
  15. Horwitz W (1980). AOCS, official methods of analysis of the association of official analytical chemist, 13th Edn. Washington DC, USA, 7, 56-132.
  16. Huang W, Zou K (2011). Cytotoxicity of a plant steroidal saponin on human lung cancer cells. Asian Pac J Cancer Prev, 12, 513-7.
  17. IARC (2012). International agency for research on cancer, GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from:
  18. Johnson IS, Armstrong JG, Gorman M, et al (1963). The vinca alkaloids: A new class of oncolytic agents. Cancer Res, 23, 1390-427.
  19. Kma L (2013). Roles of plant extracts and constituents in cervical cancer therapy. Asian Pac J Cancer Prev, 14, 3429-36.
  20. Laitiff AA, Teoh SL, Das S (2010). Wound healing in diabetes mellitus: traditional treatment modalities. Clin Ter, 161, 359-64.
  21. Liu L, Howe P, Zhou YF, et al (2000). Fatty acids and betacarotene in Australian purslane (Portulaca oleracea) varieties. J Chromatogr A, 893, 207-13.
  22. Moon JY, Mosaddik A, Kim H, et al (2011). The chloroform fraction of guava (Psidium cattleianum sabine) leaf extract inhibits human gastric cancer cell proliferation via induction of apoptosis. Food Chem, 125, 369-75.
  23. Pal SK, Shukla Y (2003). Herbal medicine: current status and the future. Asian Pac J Cancer Prev, 4, 281-8.
  24. Parry O, Marks JA, Okwuasaba FK (1993). The skeletal muscle relaxant action of Portulaca oleracea: role of potassium ions. J Ethnopharmacol, 40, 187-94.
  25. Rashed AN, Afifi FU, Disi AM (2003). Simple evaluation of the wound healing activity of a crude extract of Portulaca oleracea L. (growing in Jordan) in Musmusculus JVI-1. J Ethnopharmacol, 88, 131-36.
  26. Sarah TG, MunWong K, Pearle-Wong GO, et al (2013). In vitro cytotoxic and antiproliferative effects of Portulaca oleracea methanol extract on breast, cervical, colon and nasopharyngeal cancerous cell lines. Sains Malaysiana, 42, 927-35.
  27. Sasipawan M, Weerapreeyakul N, Barusrux S, et al (2011). Cytotoxic and apoptotic effects of six herbal plants against the human hepatocarcinoma (HepG2) cell line. Chin Med, 6, 39.
  28. Siddiqui MA, Kashyap MP, Kumar V, et al (2010). Protective potential of trans-resveratrol against 4-hydroxynonenal induced damage in PC12 cells. Toxicol In vitro, 24, 1592-8.
  29. Siddiqui MA, Singh G, Kashyap MP, et al (2008). Influence of cytotoxic doses of 4-hydroxynonenal on selected neurotransmitter receptors in PC-12 cells. Toxicol In vitro, 22, 1681-8.
  30. Uddin MK, Juraimi AS, Ali ME, et al (2012). Evaluation of antioxidant properties and mineral composition of purslane (Portulaca oleracea l.) at different growth stages. Int J Mol Sci, 13, 10257-67.
  31. Uddin MK, Juraimi AS, Hossain MS, et al (2014). Purslane weed (Portulaca oleracea): a prospective plant source of nutrition, omega-3 fatty acid, and antioxidant attributes. Scientific World J, 951019, 1-6.
  32. Wall MEMC, Wani CE, Cook KH, et al (1966). Palmer ATM, Sim GA. Plant Antitumor Agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Amer Chem Soc, 88, 3888-90.
  33. Wani C, Taylor HL, Wall ME, et al (1971). Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Amer Chem Soc, 93, 2325-27.
  34. Yang Z, Liu C, Xiang L, et al (2009). Phenolic alkaloids as a new class of antioxidants in Portulaca oleracea. Phytother Res, 23, 1032-5.
  35. Yoon JW, Ham SS, Jun HS (1999). Portulaca oleracea and tumor cell growth. US Patent. 5869060. Washington DC: Patent and Trademark Office.
  36. Zhang XJ, Ji YB, Qu ZY, et al (2002). Experimental studies on antibiotic functions of Portulaca oleracea L. in vitro. Chin J Microbiol Immunol, 14, 277-280.
  37. Zhao R, Gao X, Cai Y, et al (2013). Antitumor activity of Portulaca oleracea L. polysaccharides against cervical carcinoma in vitro and in vivo. Carbohydrate Polymers, 96, 376-83.

Cited by

  1. Separation and Identification of Four New Compounds with Antibacterial Activity from Portulaca oleracea L. vol.20, pp.9, 2015,
  2. Verbesina encelioides: cytotoxicity, cell cycle arrest, and oxidative DNA damage in human liver cancer (HepG2) cell line vol.16, pp.1, 2016,
  3. B Pathway vol.2017, pp.1741-4288, 2017,
  4. extract can inhibit nodule formation of colon cancer stem cells by regulating gene expression of the Notch signal transduction pathway vol.39, pp.7, 2017,
  5. L. seeds in streptozotocin-induced diabetic rats pp.1478-6427, 2017,
  6. Assessment of the efficacy of a new complex antisensitive skin cream pp.14732130, 2018,